Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia
https://doi.org/10.31363/2313-7053-2025-2-1147
Abstract
The aim of the study was to analyze the pathogenesis and treatment strategies of treatment-resistant schizophrenia by searching, selecting and reviewing publications covering this topic. 42 articles were analyzed during the work, which contributed to the conclusion about the effectiveness and good tolerability of third-generation antipsychotics in patients with resistant schizophrenia taking clozapine, and also to formulate the conclusion that third-generation antipsychotics can be effective in such cases.
About the Authors
A. R. Asadullin
Bashkir State Medical University
Russian Federation
Russian Federation
Azat R. Asadullin
Uf
P. O. Bomov
North-Western State Medical University named after I.I. Mechnicov
Russian Federation
Russian Federation
Pavel O. Bomov
St. Petersburg
Yu. A. Bogod
North-Western State Medical University named after I.I. Mechnicov
Russian Federation
Russian Federation
Yulia A. Bogod
St. Petersburg
References
1. Dorofeykova MV, Petrova NN. Personalized approach to the treatment of depression in schizophrenia. Sovremennaya terapiya psihicheskih rasstrojstv. 2021;3:39-46. (In Russ.).
2. Kotsyubinskij A.P. Isaenko Yu.V., Protasov A.R., Butoma B.G., Stepanova A.V., Stepanova A.A. Differencirovannyj podhod k terapii shizotipicheskogo rasstrojstva. Diagnostika i lechenie psihicheskih i narkologicheskih rasstrojstv: sovremennye podhody. Sbornik metodicheskih rekomendacij. Sost. N.V. Semenova, pod obshch. red. N.G. Neznanova. Vypusk 7. — SPb.: Izdatel’sko- poligraficheskaya kompaniya «KOSTA», 2024. (In Russ.).
3. Sychev DA, Otdelеnov VA, Krasnova NM, Il’ina ES. Polypragmasy: A clinical pharmacologist’s view. Terapevticheskij arhiv. 2016;88(12):94102. (In Russ.). DOI: 10.17116/terarkh2016881294-102
4. Chakrabarti S. Clozapine resistant schizophrenia: newer avenues of management. World Journal of Psychiatry. 2021;11(8):429. DOI: 10.5498/wjp.v11. i8.429
5. Chan SKW et al. Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12year follow-up study of first-episode schizophrenia-spectrum disorders. Schizophrenia bulletin. 2021;47(2):485-494. DOI: 10.1093/schbul/sbaa145
6. Chan SKW et al. Clozapine dosing patterns and clinical outcomes in patients with treatment resistant schizophrenia. European Neuropsychopharmacology. 2023;75:67-79. DOI: 10.1016/j.euroneuro.2023.07.007
7. Dionisie V. Clozapine—serious adverse effects and clinical management. Antidotes to Toxins and Drugs. Imprint: Elsevier, 2024.
8. Diniz E et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Brazilian Journal of Psychiatry. 2023;45(5):448458. DOI: 10.47626/1516-4446-2023-3126
9. Dmuhovskis A, Taube M. Cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report. Frontiers in Psychiatry. 2024;15:52-80.
10. Efthimiou O et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet Psychiatry. 2024;11(2):102-111. DOI: 10.1016/S2215-0366(23)00366-8
11. Egyed A., Kiss D.J., Keserű G.M. The Polypharmacology of Cariprazine and its Implications to Clinical Indications. Polypharmacology: Strategies for Multi‐Target Drug Discovery. 2025.
12. Esposito CM et al. Gender differences in clinical and biochemical parameters among patients hospitalized for schizophrenia: towards precision medicine. European Archives of Psychiatry and Clinical Neuroscience. 2024;274(5):1093-1103. DOI: 10.1007/s00406-023-01644-4
13. Freibüchler A, Seifert R. Analysis of clinical studies on clozapine from 2012-2022. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(12):9745-9765. DOI: 10.1007/s00210-024-03209-1
14. Generoso MB et al. Cariprazine for treating psychosis: an updated meta-analysis. International Journal of Psychiatry in Clinical Practice. 2023;27(1):107-109. DOI: 10.1080/13651501.2022.2071740
15. Hart XM et al. Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis. Psychopharmacology. 2022;239(11):3377-3391. DOI: 10.1007/s00213-022-06233-2
16. Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nature Reviews Neurology. 2024;20(1):2235. DOI: 10.1038/s41582-023-00904-0
17. Legge SE et al. Clinical indicators of treatment-resistant psychosis. The British Journal of Psychiatry. 2020;216(5):259-266. DOI: 10.1192/bjp.2019.120
18. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA Psychiatry United States. 2020;77:201–10. DOI: 10.1001/jamapsychiatry.2019.3360
19. Jiang Y et al. Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. Journal of Affective Disorders. 2024;346:223-229.
20. Li Y et al. Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition. Frontiers in Psychiatry. 2024;15:1444843. DOI: 10.3389/fpsyt.2024.1444843
21. Luykx JJ et al. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry. 2023;10(8):644-652. DOI: 10.1016/S2215-0366(23)00109-8
22. Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? Frontiers in Psychiatry. 2022;12:19-46. DOI: 10.3389/fpsyt.2021.781946
23. Németh G et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet. 2017;389(10074):1103-1113. DOI: 10.1016/S0140-6736(17)30060-0
24. Nucifora Jr FC et al. Clozapine as a model for antipsychotic development. Neurotherapeutics.2017;14(3):750-761. DOI: 10.1007/s13311-017-0552-9
25. Ortiz BB et al. A symptom combination predicting treatment-resistant schizophrenia–A strategy for real-world clinical practice. Schizophrenia research. 2020;218:195-200. DOI: 10.1016/j.schres.2020.01.002
26. Panov G. Gender-associated role in patients with schizophrenia. Is there a connection with the resistance? Frontiers in Psychiatry. 2022;13:54-55. DOI: 10.3389/fpsyt.2022.995455
27. Pappa S et al. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Therapeutic Advances in Psychopharmacology. 2022;12:45-53. DOI: 10.1177/20451253221132087
28. Petric D. Drug Interactions and Drug Interaction Checkers. Academia Letters. 2021.
29. Pirc Marolt T et al. Aripiprazole reduces liver cell division. Plos one. 2020;15(10):24-54.
30. Rantala MJ et al. Schizophrenia: The new etiological synthesis. Neuroscience & Biobehavioral Reviews. 2022;142:104894. DOI: 10.1016/j.neubiorev.2022.104894
31. Ricci V et al. Comparative analysis of third-generation antipsychotics in first-episode schizophrenia: efficacy, safety, and cognitive impacts. A narrative review. International Clinical Psychopharmacology. 2024;10-97.
32. Seppälä A et al. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia — a systematic review and meta-analysis. Schizophrenia Research. 2021;236:123-134. DOI: 10.1016/j.schres.2021.08.005
33. Schulte PFJ et al. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed? Schizophrenia Research. 2024;268:74-81. DOI: 10.1016/j.schres.2023.09.024
34. Siskind D et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. The British Journal of Psychiatry. 2022;220(3):115-120. DOI: 10.1192/bjp.2021.61
35. Siwek M et al. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Frontiers in Pharmacology. 2024;14:112 -132. DOI: 10.3389/fphar.2023.1321112
36. Smart SE et al. Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies. Psychological medicine. 2021;51(1):44-53. DOI: 10.1017/S0033291719002083
37. Tandon R et al. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophrenia research. 2024;264:1-28. DOI: 10.1016/j.schres.2023.11.015
38. Terao I, Kodama W. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treat- ment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis. Journal of Clinical Psychopharmacology. 2024;44(4):413-417. DOI: 10.1097/JCP.0000000000001862
39. Van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int Pharmacodyn Ther. 1996;160:492-494.
40. Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Frontiers in psychiatry. 2022;13:94-106. DOI: 10.3389/fpsyt.2022.1069432
41. Wagner E et al. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. Translational psychiatry. 2021;11(1):487. DOI: 10.1038/s41398-021-01613-2
42. Wesley EW et al. Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register. Schizophrenia Research. 2021;232:6876. DOI: 10.1016/j.schres.2021.05.006
Review
For citations:
Asadullin A.R., Bomov P.O., Bogod Yu.A. Use of third-generation antipsychotics in combination with clozapine in the treatment of resistant schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2025;59(2):114-121. (In Russ.) https://doi.org/10.31363/2313-7053-2025-2-1147
Views:
638
Email this article 